๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy

โœ Scribed by Vic J. Verwaal; Harm van Tinteren; Serge V. Ruth; Frans A.N. Zoetmulder


Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
91 KB
Volume
85
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

Background and Objectives

Cytoreduction with hyperthermic intraโ€peritoneal chemotherapy (HIPEC) is a treatment with a high morbidity. Optimal patients selection can possible reduce toxicity and complications.

Patients and Methods

Complications and toxicity of 102 patients were studied. Toxicity was graded according National Cancer Institute Common Toxicity Criteria (NCI CTC) classification. A complication was defined as any postโ€operative event that needed reโ€intervention. Potential patients, tumor, and treatment factors were studied on their relation to complications.

Results

Grade 3, 4, or 5 toxicity was observed in 66 patients (65%). Eight patients died of treatmentโ€related causes. Surgical complications occurred in 36 patients (35%). Fistulae were frequently encountered (18 patients). The risk of a complicated recovery was higher in carcinomatosis with recurrent colorectal cancer (Pโ€‰=โ€‰0.009) and in the case of more than five regions affected (Pโ€‰=โ€‰0.044), who had a Simplified Peritoneal Cancer (SPC) score of 13 (Pโ€‰=โ€‰0.012) and with an incomplete initial cytoreduction (Pโ€‰=โ€‰0.035). Patients with blood loss exceeding 6 L (Pโ€‰=โ€‰0.028) and those with three or more anastomoses also had an increased postโ€operative complication rate (Pโ€‰=โ€‰0.018).

Conclusions

Toxicity of cytoreduction followed by HIPEC was 65% (Grade 3โ€“5 NCI CTC), with a surgical complication rate of 35%. Patients with six or seven regions involved and those in whom complete cytoreduction cannot be reached are probably better off without this treatment. J. Surg. Oncol. 2004;85:61โ€“67. ยฉ 2004 Wileyโ€Liss, Inc.


๐Ÿ“œ SIMILAR VOLUMES


Cytoreductive surgery and intraperitonea
โœ Samuel P. Jacks; Jonathan C. Hundley; Perry Shen; Greg B. Russell; Edward A. Lev ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 79 KB

Introduction: Peritoneal carcinomatosis (PC) is associated with a dismal prognosis. Small bowel adenocarcinoma is a rare etiology for PC. Due to the rarity, poor prognosis, and lack of standard treatment, we chose to review our experience with this disease process treated with cytoreductive surgery

Results of cytoreductive surgery and hyp
โœ Gabriel Glockzin; Nabil Ghali; Sven A. Lang; Hans J. Schlitt; Pompiliu Piso ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 168 KB

## Abstract Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) provide a promising additional treatment option for selected patients with peritoneal carcinomatosis arising from colorectal cancer. Due to the aggressive surgery the concept is associated with a significa